Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Recruiting
Trial end date:
2023-04-27
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule
works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with
less amount of severe side effects.
Phase:
Phase 2
Details
Lead Sponsor:
City of Hope Medical Center OHSU Knight Cancer Institute